Non‐alcoholic fatty liver disease: Confronting the global epidemic requires better awareness

Silva, H Janaka de; Dassanayake, Anuradha S

doi:10.1111/j.1440-1746.2009.06026.x

Cited by 12 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In diagnosed NAFLD patients, biochemical changes involving increased serum ALT and GGT are commonly observed, and have been regarded as predictors for NAFLD, or as markers linked with other markers to establish a formula for predicting NAFLD and progressive fibrosis of the liver (de Alwis and Day, 2008). In the present study, the proportions of NAFLD patients with increased serum ALT and GGT levels were similar to those in a previous study (de Silva and Dassanayake, 2009). It was also found that serum enzyme levels were significantly increased in mild and moderate NAFLD patients.…”

Section: Discussionsupporting

confidence: 78%

Large-scale analysis of factors influencing nonalcoholic fatty liver disease and its relationship with liver enzymes

Chen

Shi

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Serum liver enzyme levels are often used effectively for the evaluation of nonalcoholic fatty liver disease (NAFLD). We aimed to investigate the associations between serum liver enzyme levels and risks for NAFLD in over 8000 cases in a large-scale analysis. A cross-sectional survey with multiple stages and random samplings was performed from May 2007 to May 2009 on 8102 workers at Tongji University. A questionnaire was given, assessments of physical measurements, plasma glucose, lipid profiles, and liver enzymes were made, and real-time liver ultrasounds conducted. The prevalence of NAFLD in Tongji University was 22.2%. It was higher in males than in females (P = 0.0023). The body mass index, waist-to-hip ratio, serum total triglycerides, serum total cholesterol, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT) values were all higher in the NAFLD group than in the control group. For moderate and severe NAFLD patients, the ALT, AST and GGT values were significantly Factors influencing nonalcoholic fatty liver disease increased, high density lipoprotein cholesterol was decreased, and drinking much, heavy entertainment and less exercise were more prevalent (P < 0.001). There were strong correlations between serum liver enzyme levels and NAFLD (P < 0.001), with GGT being a more sensitive marker for NAFLD than ALT or AST. ALT and GGT were independent predictors for NAFLD, and GGT was a better predictor than ALT for NAFLD.

show abstract

Section: Discussionsupporting

confidence: 78%

Large-scale analysis of factors influencing nonalcoholic fatty liver disease and its relationship with liver enzymes

Chen

Shi

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…11 Seventy per cent of GPs considered the prevalence of NAFLD in the general adult population to be 5-10%, and in many instances, NAFLD was not considered as a cause of abnormal liver enzymes despite the presence of metabolic risk factors. 13 In addition, their referral practices to hepatology services and other clinical areas for management of NAFLD remain unknown. 12 Current awareness of NAFLD by hospital specialists (other than gastroenterologists/hepatologists) and their opinions regarding management has not been studied.…”

Section: Introductionmentioning

confidence: 99%

Awareness and opinions of non‐alcoholic fatty liver disease by hospital specialists

Bergqvist

Skoien

Horsfall

et al. 2013

Internal Medicine Journal

View full text Add to dashboard Cite

Non-hepatologists appreciate the seriousness of NAFLD but appear to underestimate its prevalence, especially among their own patients despite known risk factors. Attitudes regarding simple steatosis versus NASH and appropriate monitoring of suspected NAFLD suggest that more can be done to improve the understanding of this disease among non-hepatologists. This has implications for targeting 'at-risk' populations and appropriate referral of patients to hepatology clinics.

show abstract

“…Non-alcoholic fatty liver disease (NAFLD), a spectrum of liver disorders ranging from simple steatosis to non-alcoholic steatohepatitis (NASH) and advanced hepatic fibrosis or even cirrhosis 1, is affecting a constantly increasing number of people all over the world 2,3. Silibinin, a natural antioxidant, has long been used in various liver ailments, including NAFLD, with a marked hepatoprotective efficacy 4.…”

Section: Introductionmentioning

confidence: 99%

Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver

Yao

Mao

Gao

et al. 2013

Braz J Med Biol Res

View full text Add to dashboard Cite

Our previous study has shown that reduced insulin resistance (IR) was one of the possible mechanisms for the therapeutic effect of silibinin on non-alcoholic fatty liver disease (NAFLD) in rats. In the present study, we investigated the pathways of silibinin in regulating hepatic glucose production and IR amelioration. Forty-five 4- to 6-week-old male Sprague Dawley rats were divided into a control group, an HFD group (high-fat diet for 6 weeks) and an HFD + silibinin group (high-fat diet + 0.5 mg kg-1·day-1 silibinin, starting at the beginning of the protocol). Both subcutaneous and visceral fat was measured. Homeostasis model assessment-IR index (HOMA-IR), intraperitoneal glucose tolerance test and insulin tolerance test (ITT) were performed. The expression of adipose triglyceride lipase (ATGL) and of genes associated with hepatic gluconeogenesis was evaluated. Silibinin intervention significantly protected liver function, down-regulated serum fat, and improved IR, as shown by decreased HOMA-IR and increased ITT slope. Silibinin markedly prevented visceral obesity by reducing visceral fat, enhanced lipolysis by up-regulating ATGL expression and inhibited gluconeogenesis by down-regulating associated genes such as Forkhead box O1, phosphoenolpyruvate carboxykinase and glucose-6-phosphatase. Silibinin was effective in ameliorating IR in NAFLD rats. Reduction of visceral obesity, enhancement of lipolysis and inhibition of gluconeogenesis might be the underlying mechanisms.

show abstract

Non‐alcoholic fatty liver disease: Confronting the global epidemic requires better awareness

Cited by 12 publications

References 28 publications

Large-scale analysis of factors influencing nonalcoholic fatty liver disease and its relationship with liver enzymes

Large-scale analysis of factors influencing nonalcoholic fatty liver disease and its relationship with liver enzymes

Awareness and opinions of non‐alcoholic fatty liver disease by hospital specialists

Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver

Contact Info

Product

Resources

About